Stockscreener 앱 받기
3.93
2.88%
0.11
시간 외 거래:
3.94
0.010
+0.25%
전일 마감가:
$3.82
열려 있는:
$3.88
하루 거래량:
11.19M
Relative Volume:
0.77
시가총액:
$1.75B
수익:
$285.55M
순이익/손실:
$-353.86M
주가수익비율:
-4.1364
EPS:
-0.9501
순현금흐름:
$-305.02M
1주 성능:
+3.97%
1개월 성능:
+13.91%
6개월 성능:
+55.95%
1년 성능:
+94.55%
1일 변동 폭
$3.81
$4.125
1주일 범위
$3.70
$4.23
52주 변동 폭
$1.66
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.93 | 1.80B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 업그레이드 | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-05-12 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-09 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
5 Best Penny Stocks That Could Skyrocket in 2026 - Insider Monkey
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last? - Yahoo Finance
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics (IOVA) reports Q1 loss, lags revenue estimates - MSN
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Iovance Shareholders Approve Expanded Capital Flexibility and Governance - TipRanks
Iovance (NASDAQ: IOVA) gains Australian Amtagvi approval as shareholders back larger share pool - Stock Titan
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001 - Insider Monkey
IOVA: All proposals passed; strong growth, robust pipeline, and focus on revenue and margin improvement - TradingView
Iovance Biotherapeutics: Progress With Caveats (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics (IOVA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Iovance rises as Australia approves melanoma therapy Amtagvi - MSN
IOVANCE (NASDAQ: IOVA) interim CEO reports RSU vesting and tax-share withholding - Stock Titan
IOVANCE (IOVA) Chief Medical Officer logs RSU vesting, tax-withheld shares in Form 4 - Stock Titan
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax share withholding - Stock Titan
IOVANCE (NASDAQ: IOVA) COO RSUs vest; 3,976 shares withheld for tax - Stock Titan
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance’s Amtagvi® (lifileucel) receives approval for treatment of Advanced Melanoma in Australia - BioSpectrum Asia
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption - Yahoo Finance
Iovance Biotherapeutics (IOVA) Sees Revenue Surge 45% on Amtagvi Growth Despite Analyst Price Target AdjustmentEarnings Call Highlights - newsline.com
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi - Yahoo Finance
Iovance Biotherapeutics (IOVA) Slides 3.4% as Biotech Sector Faces Renewed PressureSmart Money Flow Stocks - newsline.com
Iovance Biotherapeutics (IOVA) Up 11% Since Q1 2026, Does it Have Further Upside Potential? - Insider Monkey
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now? - Insider Monkey
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Australia approves Iovance’s Amtagvi for advanced melanoma By Investing.com - Investing.com Nigeria
IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
5 Stocks Crushing the Market With Surging Returns - Insider Monkey
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15% - Insider Monkey
IOVA: AMTAGVI’s rapid growth and strong clinical data drive expansion, with pivotal trials and new therapies advancing - TradingView
Iovance Biotherapeutics (IOVA) Secures Conditional Approval for Amtagvi in Australia - GuruFocus
Iovance wins Australian nod for melanoma drug (IOVA:NASDAQ) - Seeking Alpha
Australia approves Iovance’s Amtagvi for advanced melanoma - Investing.com Australia
Iovance’s Amtagvi granted Australian approval - The Pharma Letter
Iovance Biotherapeutics (IOVA) Receives Conditional Approval for Amtagvi in Australia - GuruFocus
Iovance stock gains after Australia approves melanoma therapy - Investing.com
Iovance stock gains after Australia approves melanoma therapy By Investing.com - Investing.com India
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Iovance Biotherapeutics Inc 주식 (IOVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
144,087 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
251,957 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
137,896 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 01 '26 |
Option Exercise |
0.00 |
41,668 |
0 |
571,206 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
5,469 |
0 |
244,699 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
8,790 |
0 |
140,747 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
8,790 |
0 |
134,556 |
| Kirby Daniel Gordon | Chief Commercial Officer |
May 11 '26 |
Option Exercise |
0.00 |
10,000 |
0 |
149,381 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 05 '26 |
Option Exercise |
0.00 |
62,493 |
0 |
556,293 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
148,477 |
2.60%
0.94%
자본화:
|
볼륨(24시간):